Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Next-Generation Gas Chromatograph and GC/MSD Enable New Levels of Performance

By BiotechDaily International staff writers
Posted on 12 Feb 2013
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
A new gas chromatograph (GC) and a mass selective detector to function with the GC offer a broad, feature-rich portfolio, and enable superior levels of sensitivity, reliability, and productivity.

Agilent Technologies (Santa Clara, CA, USA) introduces the Agilent 7890B gas chromatograph and the 5977A Series GC/MSD (mass selective detector) to offer the industry's broadest, feature-rich portfolio of superior performance GC, GC/MSD, and related software. Agilent also offers factory-tested, preconfigured solutions to help fast-track setup and operation. "Customers will find significant product improvements, eco-friendly capabilities, and lower cost of ownership, along with unsurpassed performance,” said Monty Benefiel, Agilent vice president for Gas Phase Systems.

Based on the known reliability of the Agilent GC platform, the new 7890B GC is faster, easier to operate, and more cost-effective. The 7890B GC features Improved performance specifications with advances in numerous detector modules; Lower operating costs and ecofriendly operation with power/gas management and sleep/wake modes; Seamless ordering of consumables and parts with an interactive graphical Parts Finder tool and consumables database; Easier, faster method development with integrated GC calculators and wizards; Better asset and resource management with integrated maintenance tools; Improved recovery of active compounds with Agilent's exclusive end-to-end Inert Flow Path deactivation technology; Reduced downtime for MS maintenance using the new Fast Vent feature.

The Agilent 7890B GC runs on Agilent OpenLAB Chromatography Data System software. The new Agilent OpenLAB CDS is up to 40 times faster than previous versions, with a new Data Analysis package and Intelligent Reporting. Advanced interactive integration tools and graphical displays accelerate data review, reducing time-to-results and freeing up operators for other tasks. "Our customers require the means to efficiently and accurately analyze their data as well as information about their laboratory assets to support decision making or gain further scientific insight. OpenLAB does all of that," said Bruce von Herrmann, Agilent vice president for Software and Informatics. "With streamlined workflows and complete data and method migration from ChemStation and EZChrom, OpenLAB is a fully scalable solution for a single laboratory, multiple workgroups, and entire enterprises."

The Agilent 5977A Series GC/MSD provides all the benefits of the 7890B GC plus features a redesigned inert MS ion source that enhances performance with highly efficient ion collection. The 5977A Series GC/MSD now offers the highest sensitivity on the market, with a new specification metric, the Instrument Detection Limit, for system-level performance in practice. Using Agilent's TwisTorr 304 FS turbomolecular vacuum pump, optimized for light gas operation, the new 5977A GC/MSD system is efficient and rugged, and has been evaluated and certified to meet Agilent’s leading quality standards. The GC/MSD runs on Agilent MassHunter Workstation software solution for high-throughput MS data analysis, and also includes a full version of MSD ChemStation to ensure compatibility with previously purchased instruments.

Related Links:
Agilent Technologies, Inc.
Agilent 7890B GC and 5977A Series GC/MSD
Agilent Inert Flow Path Solutions



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.